CVS Health Corp (CVS) Position Cut by Dean Investment Associates LLC

Dean Investment Associates LLC trimmed its position in CVS Health Corp (NYSE:CVS) by 4.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 81,893 shares of the pharmacy operator’s stock after selling 3,527 shares during the quarter. CVS Health accounts for 0.9% of Dean Investment Associates LLC’s holdings, making the stock its 22nd largest holding. Dean Investment Associates LLC’s holdings in CVS Health were worth $5,937,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in CVS. Fieldpoint Private Securities LLC grew its stake in shares of CVS Health by 333.3% during the second quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock worth $105,000 after buying an additional 1,000 shares during the last quarter. Wealthcare Advisory Partners LLC grew its stake in shares of CVS Health by 330.3% during the third quarter. Wealthcare Advisory Partners LLC now owns 1,291 shares of the pharmacy operator’s stock worth $105,000 after buying an additional 991 shares during the last quarter. Arcadia Investment Management Corp MI grew its stake in shares of CVS Health by 119.6% during the third quarter. Arcadia Investment Management Corp MI now owns 1,333 shares of the pharmacy operator’s stock worth $108,000 after buying an additional 726 shares during the last quarter. MPS Loria Financial Planners LLC bought a new stake in shares of CVS Health in the second quarter worth $119,000. Finally, Cerebellum GP LLC bought a new stake in shares of CVS Health in the fourth quarter worth $130,000. 83.96% of the stock is currently owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

In related news, EVP Helena Foulkes sold 19,965 shares of the business’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $71.04, for a total value of $1,418,313.60. Following the transaction, the executive vice president now owns 65,072 shares in the company, valued at $4,622,714.88. The transaction was disclosed in a document filed with the SEC, which is available through this link. 0.61% of the stock is owned by insiders.

Several brokerages recently weighed in on CVS. Needham & Company LLC set a $98.00 price objective on shares of CVS Health and gave the stock a “buy” rating in a research note on Friday, February 9th. ValuEngine cut shares of CVS Health from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. Leerink Swann set a $85.00 price objective on shares of CVS Health and gave the stock a “buy” rating in a research note on Friday, February 9th. Loop Capital set a $73.00 price objective on shares of CVS Health and gave the stock a “hold” rating in a research note on Monday, December 4th. Finally, Deutsche Bank reissued a “hold” rating on shares of CVS Health in a research note on Tuesday, December 5th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $87.03.

CVS Health stock opened at $60.86 on Friday. The stock has a market cap of $61,744.42, a price-to-earnings ratio of 10.28, a P/E/G ratio of 1.00 and a beta of 1.03. The company has a quick ratio of 0.52, a current ratio of 1.02 and a debt-to-equity ratio of 0.59. CVS Health Corp has a fifty-two week low of $60.78 and a fifty-two week high of $84.00.

CVS Health (NYSE:CVS) last released its earnings results on Thursday, February 8th. The pharmacy operator reported $1.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.88 by $0.04. The business had revenue of $48.39 billion for the quarter, compared to analyst estimates of $47.54 billion. CVS Health had a net margin of 3.58% and a return on equity of 17.21%. CVS Health’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.71 earnings per share. equities analysts expect that CVS Health Corp will post 6.37 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, May 3rd. Investors of record on Monday, April 23rd will be issued a $0.50 dividend. The ex-dividend date of this dividend is Friday, April 20th. This represents a $2.00 annualized dividend and a yield of 3.29%. CVS Health’s payout ratio is 30.91%.

COPYRIGHT VIOLATION WARNING: This report was originally published by Ticker Report and is the property of of Ticker Report. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/3298541/cvs-health-corp-cvs-position-cut-by-dean-investment-associates-llc.html.

CVS Health Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Park-Ohio Holdings Corp.  Given Average Recommendation of “Hold” by Brokerages
Park-Ohio Holdings Corp. Given Average Recommendation of “Hold” by Brokerages
Contrasting resTORbio  and BioLineRx
Contrasting resTORbio and BioLineRx
Contrasting MarineMax  & U.S. Auto Parts
Contrasting MarineMax & U.S. Auto Parts
Target  and Its Rivals Critical Review
Target and Its Rivals Critical Review
Somewhat Positive Media Coverage Somewhat Unlikely to Impact Formula Systems  Stock Price
Somewhat Positive Media Coverage Somewhat Unlikely to Impact Formula Systems Stock Price
Somewhat Positive News Coverage Somewhat Unlikely to Impact SandRidge Energy  Share Price
Somewhat Positive News Coverage Somewhat Unlikely to Impact SandRidge Energy Share Price


© 2006-2018 Ticker Report. Google+.